Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano
Masashi
M
Kato
Masafumi
M
Yoshikawa
Tomoyuki
T
Goto
Tomoko
T
Furuya
Kenichi
K
Kikuchi
Yoshihiro
Y
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000378:metabolism; D044466:Asian People / Q000235:genetics*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D007564:Japan; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000208:ethnology / Q000235:genetics; D009503:Neutropenia / Q000139:chemically induced* / Q000235:genetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D000099148:UGT1A1 Enzyme
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D000099148:UGT1A1 Enzyme